-+ 0.00%
-+ 0.00%
-+ 0.00%

Valneva's Shigella Vaccine Meets Primary Endpoint in Phase 2 Trial

PUBT·11/09/2026 06:00:43
Listen to the news
Valneva's Shigella Vaccine Meets Primary Endpoint in Phase 2 Trial
  • Valneva today announced positive results from two Phase 2 trials of its Shigella vaccine candidate S4V2.
  • The adult challenge trial met its primary endpoint, reducing shigellosis versus placebo.
  • Infant results showed immune responses against all four targeted serotypes, with antibodies remaining above baseline six months later.
  • Both trials showed favorable safety profiles.
  • Full datasets remain under review to guide further clinical development, including dose selection and vaccination schedules.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090100PRIMZONEFULLFEED1001302295) on November 09, 2026, and is solely responsible for the information contained therein.